Article
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Annals of surgical oncology - 1 May 2014
Kwa Maryann, Edwards Susan, Downey Andrea, Reich Elsa, Wallach Robert, Curtin John, Muggia Franco
Abstract excerpt
BACKGROUND: Ovarian cancer arising in women with BRCA mutations is known to have a more favorable outcome and to be more responsive to platinum-based regimens than in those without a hereditary background. We analyze our previously published intraperitoneal (IP) studies in relation to BRCA mutation status and update their outcomes. METHODS: Among 62 patients with ovarian cancer enrolled in IP platinum doublet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.